Patents Assigned to Merck Patent Gesellschaft mit beschrankter
  • 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS
    Publication number: 20120172396
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: February 7, 2012
    Publication date: July 5, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Denis CARNIATO, Christine CHARON, Johannes GLEITZ, Didier ROCHE, Bjoern HOCK
  • Thiadiazinone derivatives
    Patent number: 8211886
    Abstract: Compounds of the formula (I), which are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed for the treatment of tumours.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: July 3, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Oliver Schadt, Dieter Dorsch, Frank Stieber, Andree Blaukat
  • Liquid-crystalline compounds and liquid-crystalline media
    Patent number: 8211513
    Abstract: The present invention relates to liquid-crystalline compounds having at least three fluorine-substituted benzene rings, a terminal trifluoromethyl group and at least one —CF2O— bridge. The invention also relates to liquid-crystalline media prepared therewith and to liquid-crystal display devices (LC displays) containing these media.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: July 3, 2012
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Axel Jansen, Helmut Haensel, Philipp Krattiger, Andreas Taugerbeck, Malgorzata Rillich
  • LIQUID CRYSTALLINE MEDIUM
    Publication number: 20120161073
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds having negative dielectric anisotropy, which contains at least one compound of the formula I and at least one compound of the formula II in which R1, R2, R3, R4, ring A, Z1, Z2 and m are as defined in Claim 1, and to the use thereof for an active-matrix display based on the ECB, VA, PS-VA, FFS, PALO or IPS effect.
    Type: Application
    Filed: February 29, 2012
    Publication date: June 28, 2012
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Norihiko TANAKA, Makoto Murakami, Shinji Nakajima
  • SOLUTION PROCESSABLE PASSIVATION LAYERS FOR ORGANIC ELECTRONIC DEVICES
    Publication number: 20120153285
    Abstract: The present invention relates to solution processable passivation layers for organic electronic (OE) devices, and to OE devices, in particular organic field effect transistors (OFETs), comprising such passivation layers.
    Type: Application
    Filed: August 6, 2010
    Publication date: June 21, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Mark James, Nils Greinert, Miguel Carrasco-Orozco, Paul Craig Brookes, David Christoph Mueller, Philip Edward May, Stephen Armstrong, Sivanand Pennadam
  • 5-cyanothienopyridines for the treatment of tumours
    Patent number: 8202882
    Abstract: Novel 5-cyanothienopyridines of the formula (I), in which R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: June 19, 2012
    Assignee: Merck Patent Gesellschaft MIT Beschränkter Haftung
    Inventors: Guenter Hoelzemann, Ulrich Graedler, Hartmut Greiner, Christiane Amendt, Djordje Musil, Per Hillertz
  • Polymorphic forms and process
    Patent number: 8198452
    Abstract: The invention relates to a process for the manufacture of enantiomerically enriched or pure compounds of formula I wherein R1, R2, R3, R6, R7 and Q are defined as in claim 1 as well as their crystalline forms for the treatment of proliferative diseases such as cancer.
    Type: Grant
    Filed: May 26, 2007
    Date of Patent: June 12, 2012
    Assignee: Merck Patent Gesellschaft MIT Beschränkter Haftung
    Inventors: Kai Schiemann, Ulrich Emde, Tobias Schlueter, Christoph Saal, Michael Maiwald
  • PHENANTHROl[1,10,9,8-C,D,E,F,G]CARBAZOLE POLYMERS AND THEIR USE AS ORGANIC SEMICONDUCTORS
    Publication number: 20120138865
    Abstract: The invention relates to novel phenanthro[1,10,9,8-c,d,e,f,g]carbazole polymers, methods and materials for their preparation, their use as semiconductors in organic electronic (OE) devices, and to OE devices comprising these polymers.
    Type: Application
    Filed: July 14, 2010
    Publication date: June 7, 2012
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Nicolas Blouin, William Mitchell, Changsheng Wang, Steven Tierney
  • CO-DOPED SILICOOXYNITRIDES
    Publication number: 20120140438
    Abstract: The invention relates to compounds of the formula (I) (Ca,Sr,Ba)6-X(Si1-y Mey)3(O1-zMa2z)6N4:Eux (I), where Me=Th, Ru and/or Os Ma?F and/or Cl, x<0.5, y<1 and z<0.1, and to a process for the preparation of these compounds and use as phosphors and conversion phosphors for the conversion of the blue or near-UV emission from an LED.
    Type: Application
    Filed: June 17, 2010
    Publication date: June 7, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Holger Winkler, Ralf Petry, Tim Vosgroene, Thomas Juestel, Dominik Uhlich, Arturas Katelnikovas
  • 2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors
    Patent number: 8188288
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: May 29, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Denis Carniato, Christine Charon, Johannes Gleitz, Didier Roche, Bjoern Hock
  • Binding agent
    Patent number: 8188180
    Abstract: The present invention relates to binders, to processes for the preparation thereof, and to the use thereof in formulations, surface coatings, inks and plastics.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: May 29, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Gerhard Jonschker, Joerg Pahnke, Johanna Schuetz-Widoniak, Matthias Koch
  • ELECTROLYTE SYSTEM
    Publication number: 20120127631
    Abstract: The present invention relates to electrolyte systems and electrochemical cells comprising conductive salts having different anionic and/or cationic radii.
    Type: Application
    Filed: July 6, 2010
    Publication date: May 24, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Michael Schmidt, Guenter Semrau
  • 1,3-dihydroisoindole derivatives
    Patent number: 8183279
    Abstract: Novel 1,3-dihydroisoindole derivatives of the formula (I), in which R1-R3 have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: May 22, 2012
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Hans Michael Eggenweiler, Christian Sirrenberg, Hans Peter Buchstaller
  • E-POLYLYSINE CONJUGATES AND THE USE THEREOF
    Publication number: 20120122788
    Abstract: The present invention relates to ?-polylysine conjugates, in particular conjugates of ?-polylysine with compounds carrying carboxyl groups, and to the preparation and use thereof for targeting of the kidney.
    Type: Application
    Filed: July 9, 2010
    Publication date: May 17, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Armin Kuebelbeck, Gregor Larbig, Walter Mier, Barbro Beijer, Uwe Haberkorn
  • TABLETING AGENT HAVING A LOW WATER CONTENT, AND METHOD FOR THE PRODUCTION THEREOF
    Publication number: 20120114717
    Abstract: The present invention relates to a Tabletting aid with a low water content and to a process for the preparation thereof. The Tabletting aid composition is a directly compressible composition, the use of which results in improved tablet properties.
    Type: Application
    Filed: July 7, 2010
    Publication date: May 10, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: James Easson, Walter Hamm, Guenter Moddelmog
  • AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES
    Publication number: 20120115861
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R7 and Y have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumours and for the treatment of inflammatory diseases.
    Type: Application
    Filed: June 17, 2010
    Publication date: May 10, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Michel Calderini, Margarita Wucherer-Plietker, Ulrich Graedler, Christina Esdar
  • HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS
    Publication number: 20120115852
    Abstract: Compounds of the formula (I), in which R, R1, R2, X, X1, Y, Y1, Q, E, n1 and n2 have the meanings indicated in claim 1, are autotaxin inhibitors and can be employed for the treatment of tumours.
    Type: Application
    Filed: June 17, 2010
    Publication date: May 10, 2012
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Melanie Schultz, Kai Schiemann, Wolfgang Staehle
  • FLUOROSURFACTANTS
    Publication number: 20120111233
    Abstract: The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to processes for the preparation of these compounds.
    Type: Application
    Filed: June 1, 2010
    Publication date: May 10, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Wolfgang Hierse, Eckhard Claus, Jan Krause, Melanie Kleineidam, Steffen Schellenberger, Andreas Bathe
  • Polymers derived from bis(thienocyclopenta) benzothiadiazole and their use as organic semiconductors
    Patent number: 8173766
    Abstract: The invention relates to conjugated polymers comprising bis(thienocyclopenta)benzothiadiazole units or derivatives thereof, to methods of their preparation, to novel monomer units used therein, to the use of the polymers in organic electronic (OE) devices, and to OE devices comprising the polymers.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: May 8, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Steven Tierney, Clare Bailey, William Mitchell
  • Liquid-crystalline medium
    Patent number: 8168081
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of dielectrically negative, polar compounds which comprises at least one compound of the formula I in which the parameters have the meanings indicated in claim 1, to the use thereof in an electro-optical display, particularly in an active-matrix display based on the VA, ECB, PALC, FFS or IPS effect, and to displays of this type.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: May 1, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Melanie Klasen-Memmer, Georg Bernatz, Izumi Saito, Matthias Bremer, Lars Lietzau, Volker Reiffenrath